Keith Fay

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar et al. · The Lancet Oncology · 2022 · 436 citations · Full text

Medicine, Clinical Sciences, Oncology +16

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Nancy L. Bartlett, Sarit Assouline, Pratyush Giri et al. · Blood Advances · 2023 · 93 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Laurie H. Sehn, Nancy L. Bartlett, Matthew J. Matasar et al. · Blood · 2024 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar et al. · Blood · 2022 · 31 citations

Pharmacy, Oncology, Pharmacotherapy +15

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Nancy L. Bartlett, Pratyush Giri, Stephen J. Schuster et al. · Blood · 2022 · 23 citations

Medicine, Pharmacology, Pharmacotherapy +16